Literature DB >> 21549322

Response to Frederic Bretzner et al. "Target populations for first-in-human embryonic stem cell research in spinal cord injury".

Edward Wirth1, Jane S Lebkowski, Karen Lebacqz.   

Abstract

We address concerns raised in this issue by Bretzner et al. (2011) by explaining the rationale for including subjects with subacute, neurologically complete spinal cord injuries in the Phase 1 trial of GRNOPC1. We also present elements of the informed consent process that minimize the likelihood of therapeutic misconception.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Year:  2011        PMID： 21549322     DOI： 10.1016/j.stem.2011.04.008

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN： 1875-9777            Impact factor:   24.633


  14 in total

Review 1.  Ethical development of stem-cell-based interventions.

Authors:  Amanda MacPherson; Jonathan Kimmelman
Journal:  Nat Med       Date:  2019-07-03       Impact factor: 53.440

2.  The risk-escalation model: a principled design strategy for early-phase trials.

Authors:  Spencer Phillips Hey; Jonathan Kimmelman
Journal:  Kennedy Inst Ethics J       Date:  2014-06

3.  One Size Fits All?: Ethical Considerations for Examining Efficacy in First-in-Human Pluripotent Stem Cell Studies.

Authors:  Michelle Gjl Habets; Johannes Jm van Delden; Sophie L Niemansburg; Harold L Atkins; Annelien L Bredenoord
Journal:  Mol Ther       Date:  2016-12       Impact factor: 11.454

Review 4.  Human pluripotent stem cells: Towards therapeutic development for the treatment of lifestyle diseases.

Authors:  Miwako Nishio; Masako Nakahara; Akira Yuo; Kumiko Saeki
Journal:  World J Stem Cells       Date:  2016-02-26       Impact factor: 5.326

Review 5.  Modulating the stem cell niche for tissue regeneration.

Authors:  Steven W Lane; David A Williams; Fiona M Watt
Journal:  Nat Biotechnol       Date:  2014-08       Impact factor: 54.908

6.  An effective approach to prevent immune rejection of human ESC-derived allografts.

Authors:  Zhili Rong; Meiyan Wang; Zheng Hu; Martin Stradner; Shengyun Zhu; Huijuan Kong; Huanfa Yi; Ananda Goldrath; Yong-Guang Yang; Yang Xu; Xuemei Fu
Journal:  Cell Stem Cell       Date:  2014-01-02       Impact factor: 24.633

Review 7.  What is the potential of oligodendrocyte progenitor cells to successfully treat human spinal cord injury?

Authors:  Robert A Watson; Trevor M Yeung
Journal:  BMC Neurol       Date:  2011-09-23       Impact factor: 2.474

Review 8.  Ethical challenges for a new generation of early-phase pediatric gene therapy trials.

Authors:  Alexander A Iyer; Dimah Saade; Diana Bharucha-Goebel; A Reghan Foley; Gilberto 'Mike' Averion; Eduardo Paredes; Steven Gray; Carsten G Bönnemann; Christine Grady; Saskia Hendriks; Annette Rid
Journal:  Genet Med       Date:  2021-07-07       Impact factor: 8.822

9.  Bioprocessing of cryopreservation for large-scale banking of human pluripotent stem cells.

Authors:  Yan Li; Teng Ma
Journal:  Biores Open Access       Date:  2012-10

Review 10.  Current status of drug screening and disease modelling in human pluripotent stem cells.

Authors:  Divya Rajamohan; Elena Matsa; Spandan Kalra; James Crutchley; Asha Patel; Vinoj George; Chris Denning
Journal:  Bioessays       Date:  2012-08-08       Impact factor: 4.345
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.